| DIRECT COMPETITOR COMPARISON | |
| QLTI | AGN | Pvt1 | REGN | Industry | | Market Cap: | 263.32M | 17.72B | N/A | 1.46B | 100.26M | | Employees: | 135 | 8,300 | 11,1741 | 967 | 65 | | Qtrly Rev Growth (yoy): | -19.20% | 3.90% | N/A | 79.10% | 19.70% | | Revenue (ttm): | 118.97M | 4.34B | 13.42B1 | 338.30M | 14.05M | | Gross Margin (ttm): | 33.84% | 83.19% | N/A | -0.70% | 65.67% | | EBITDA (ttm): | 21.60M | 1.13B | N/A | -58.93M | -12.30M | | Oper Margins (ttm): | 16.94% | 22.19% | N/A | -20.95% | -137.11% | | Net Income (ttm): | 22.11M | 561.90M | N/A | -64.43M | N/A | | EPS (ttm): | 0.403 | 1.842 | N/A | -0.810 | -0.32 | | P/E (ttm): | 11.96 | 31.64 | N/A | N/A | 16.37 | | PEG (5 yr expected): | N/A | 1.63 | N/A | N/A | 1.31 | | P/S (ttm): | 2.07 | 4.16 | N/A | 4.36 | 9.43 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.21 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | REGN | | Sanofi Expands Regeneron Agreement
Wed, Nov 25 -
Zacks.com | | • | REGN | | 4 Platform Drugmakers to Invest In
Tue, Nov 24 -
at Motley Fool | | • | REGN | | Regeneron Announces Presentation at the 21st Annual Piper Jaffray Healthcare Conference
Tue, Nov 24 -
PR Newswire | | • | AGN | | AEGON Announces Offering of USD 500 Million of 4.625% Senior Notes
Tue, Nov 24 -
PR Newswire | | • | AGN | | [video] Healthcare Stocks: Safe and Speculative
Mon, Nov 23 -
at TheStreet.com | | • | AGN | | [$$] Banks Flexing Their M&A Muscles
Mon, Nov 23 -
at RealMoney by TheStreet.com | | • | AGN | | UPDATE - Spectrum inks deal with Korea's Handok for cancer drug
Mon, Nov 23 -
at Reuters | | • | AGN | | Winners, losers in U.S. Senate health bill
Sat, Nov 21 -
at Reuters | | • | REGN | | Big Pharma Willing to Pay for Biotech Innovation
Sun, Nov 15 -
at Seeking Alpha | | • | REGN | | Drug Companies Should Think Smaller
Thu, Nov 12 -
at Motley Fool | | • | REGN | | REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an
Thu, Nov 12 -
EDGAR Online | | • | REGN | | Regeneron, Sanofi-Aventis to Continue Collaboration
Wed, Nov 11 -
at Fox Business | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 
0.32 (7.11%) 
Competitors
